Analysis: Investment risks of fast-tracking biotech drugs become apparent
from Reuters via Chicago Tribune
With biotech's bull run nearing its third year, some savvy investors believe it is time to seek safety in size. The promise of drugs reaching the market at a faster pace has overshadowed rising risk in the sector. But signs in the past few months that a booming IPO market may be peaking and reversals for some fast-tracked drugs are starting to give investors second thoughts about expensive smaller-cap biotechs.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063